Investors remain reluctant to give NuVasive (NUVA) much benefit of the doubt, and based upon the company’s recent performance, I can’t say I blame them. Although I wrote back in January that I thought it would take time for the company to rebuild investor confidence, I’m still surprised to see the nearly 10% drop in the share price over that period, while Globus Medical (GMED) has shot up nearly 20% and K2M (KTWO) has risen close to 10%.
There are a lot of issues with NuVasive right now, including a fairly spotty history of earnings quality, worries about competitors poaching away....More>>>